Comparison of Rifabutin- and Levofloxacin-based Third-line Rescue Therapies for Helicobacter pylori.
10.4166/kjg.2012.59.6.401
- Author:
Myung Ho JEONG
1
;
Jun Won CHUNG
;
Sang Jin LEE
;
Minsu HA
;
Seok Hoo JEONG
;
Sunyoung NA
;
Byung Soo NA
;
Sung Keun PARK
;
Yoon Jae KIM
;
Kwang An KWON
;
Kwang Il KO
;
Yunjeong JO
;
Ki Baik HAHM
;
Hwoon Yong JUNG
Author Information
1. Department of Internal Medicine, Gachon Graduate School of Medicine, Incheon, Korea. drgreen@gilhospital.com
- Publication Type:Original Article ; Comparative Study ; English Abstract
- Keywords:
Helicobacter pylori;
Rifabutin;
Levofloxacin;
Third line;
Salvage therapy
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Amoxicillin/therapeutic use;
Anti-Bacterial Agents/*therapeutic use;
Breath Tests;
Drug Resistance, Bacterial/drug effects;
Drug Therapy, Combination;
Female;
Helicobacter Infections/*drug therapy;
Helicobacter pylori;
Humans;
Male;
Middle Aged;
Ofloxacin/*therapeutic use;
Proton Pump Inhibitors/therapeutic use;
Rifabutin/*therapeutic use;
Salvage Therapy
- From:The Korean Journal of Gastroenterology
2012;59(6):401-406
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: There is increasing need for third-line therapy of Helicobacter pylori due to increasing level of antibiotics resistance. The aim of this study was to compare rifabutin and levofloxacin rescue regimens in patients with first- and second-line Helicobacter pylori eradication failures. METHODS: Patients, in whom a first treatment with proton pump inhibitor-clarithromycin-amoxicillin and a second trial with proton pump inhibitor-bismuth-tetracycline-metronidazole had failed, received treatment with either rifabutin or levofloxacin, plus amoxicillin (1 g twice daily) and standard dose proton pump inhibitor. Eradication rates were confirmed with 13C-urea breath test or rapid urease test 4 weeks after the cessation of therapy. RESULTS: Eradication rates were 71.4% in the rifabutin group, and 57.1% in the levofloxacin group, respectively. Although there was no significant difference in Helicobacter pylori eradication rates between two groups (p=0.656), rifabutin based regimen showed relatively higher eradication rate. CONCLUSIONS: Helicobacter pylori eradication rates of rifabutin- or levofloxacin-based triple therapy could not achieve enough eradication rate. Further studies would be needed on combination of levofloxacin and rifabutin-based regimen or culture based treatment.
